Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 16 07 2019
revised: 24 05 2020
accepted: 29 06 2020
pubmed: 31 7 2020
medline: 26 11 2021
entrez: 31 7 2020
Statut: ppublish

Résumé

The purpose of this study was to measure genomic changes that emerge with enzalutamide treatment using analyses of whole-genome sequencing and RNA sequencing. One hundred and one tumors from men with metastatic castration-resistant prostate cancer (mCRPC) who had not been treated with enzalutamide ( Copy number loss was more common than gain in enzalutamide-resistant tumors. Specially, we identified 124 protein-coding genes that were more commonly lost in enzalutamide-resistant samples. These 124 genes included eight putative tumor suppressors located at nine distinct genomic regions. We demonstrated that focal deletion of the 17q22 locus that includes Copy number loss is common in enzalutamide-resistant tumors. Focal deletion of chromosome 17q22 defines a previously unappreciated molecular subset of enzalutamide-resistant mCRPC associated with poor clinical outcome.

Identifiants

pubmed: 32727885
pii: 1078-0432.CCR-19-2303
doi: 10.1158/1078-0432.CCR-19-2303
pmc: PMC7484240
mid: NIHMS1609735
doi:

Substances chimiques

Benzamides 0
Biomarkers, Tumor 0
Nitriles 0
Phenylthiohydantoin 2010-15-3
enzalutamide 93T0T9GKNU

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

4616-4624

Subventions

Organisme : NLM NIH HHS
ID : K01 LM012877
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA093373
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097186
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

Clin Cancer Res. 2019 Feb 1;25(3):928-936
pubmed: 30037818
Nucleic Acids Res. 2019 Jan 8;47(D1):D786-D792
pubmed: 30304474
Genome Biol. 2014;15(12):550
pubmed: 25516281
Mol Cancer Res. 2014 Sep;12(9):1195-204
pubmed: 24807918
Nat Rev Cancer. 2016 Jul;16(7):413-30
pubmed: 27282250
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Science. 2009 May 8;324(5928):787-90
pubmed: 19359544
Ann Oncol. 2018 Feb 1;29(2):352-360
pubmed: 29069303
J Clin Oncol. 2014 Mar 1;32(7):671-7
pubmed: 24449231
PLoS Genet. 2016 Apr 19;12(4):e1005895
pubmed: 27093186
Lancet. 2010 Apr 24;375(9724):1437-46
pubmed: 20398925
PLoS One. 2015 Dec 22;10(12):e0145176
pubmed: 26695660
Cancer Cell. 2017 Aug 14;32(2):204-220.e15
pubmed: 28810145
Nat Genet. 2016 Aug;48(8):838-47
pubmed: 27322546
J Clin Oncol. 2019 May 1;37(13):1120-1129
pubmed: 30865549
Science. 2012 Jul 6;337(6090):104-9
pubmed: 22628553
Cancer Res. 2008 Jun 1;68(11):4447-54
pubmed: 18519708
Cell. 2013 Nov 7;155(4):948-62
pubmed: 24183448
Eur Urol. 2015 Jan;67(1):53-60
pubmed: 24882673
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Eur Urol. 2015 Jun;67(6):986-990
pubmed: 25151012
Oncogene. 2007 Dec 6;26(55):7611-9
pubmed: 17599054
Bioinformatics. 2013 Aug 15;29(16):2041-3
pubmed: 23736529
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Mol Cell. 2015 Oct 1;60(1):105-17
pubmed: 26431027
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3
pubmed: 5279523
Bioinformatics. 2016 Aug 1;32(15):2375-7
pubmed: 27153601
Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17204-9
pubmed: 15569926
J Natl Cancer Inst. 2004 Aug 18;96(16):1240-7
pubmed: 15316059
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
Mol Cancer Ther. 2016 Jul;15(7):1427-35
pubmed: 27330107
Biostatistics. 2004 Oct;5(4):557-72
pubmed: 15475419
Eur Urol. 2019 Nov;76(5):562-571
pubmed: 30928160
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
J Clin Oncol. 2008 Mar 1;26(7):1148-59
pubmed: 18309951
Mol Syst Biol. 2010 Jun 8;6:377
pubmed: 20531406
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
Cell Cycle. 2015;14(13):2142-8
pubmed: 25927139
Eur Urol. 2020 Jan;77(1):14-21
pubmed: 31176623
Urol Oncol. 2017 Aug;35(8):535
pubmed: 28623072
Cell. 2018 Oct 18;175(3):889
pubmed: 30340047
Bioinformatics. 2012 Jul 15;28(14):1811-7
pubmed: 22581179

Auteurs

Xiangnan Guan (X)

Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

Duanchen Sun (D)

Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

Eric Lu (E)

Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

Joshua A Urrutia (JA)

Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

Robert Evan Reiter (RE)

Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, California.
Jonsson Comprehensive Cancer Center, Department of Urology, University of California Los Angeles, Los Angeles, California.

Matthew Rettig (M)

Jonsson Comprehensive Cancer Center, Department of Urology, University of California Los Angeles, Los Angeles, California.
VA Greater Los Angeles, Department of Medicine, Los Angeles, California.

Christopher P Evans (CP)

University of California Davis Comprehensive Cancer Center, Sacramento, California.

Primo Lara (P)

University of California Davis Comprehensive Cancer Center, Sacramento, California.

Martin Gleave (M)

Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.

Tomasz M Beer (TM)

Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

George V Thomas (GV)

Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

Jiaoti Huang (J)

Duke University School of Medicine, Durham, North Carolina.

Rahul R Aggarwal (RR)

University of California San Francisco, San Francisco, California.

David A Quigley (DA)

University of California San Francisco, San Francisco, California.

Adam Foye (A)

University of California San Francisco, San Francisco, California.

William S Chen (WS)

University of California San Francisco, San Francisco, California.

Jack Youngren (J)

University of California San Francisco, San Francisco, California.

Alana S Weinstein (AS)

University of California Santa Cruz, Santa Cruz, California.

Joshua M Stuart (JM)

University of California Santa Cruz, Santa Cruz, California.

Felix Y Feng (FY)

University of California San Francisco, San Francisco, California.

Eric J Small (EJ)

University of California San Francisco, San Francisco, California.

Zheng Xia (Z)

Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon. jalumkal@med.umich.edu xiaz@ohsu.edu.

Joshi J Alumkal (JJ)

Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon. jalumkal@med.umich.edu xiaz@ohsu.edu.
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH